

SELECTIVE HASPIN INHIBITORS

The CNIO has developed a novel group of compounds with a tricyclic core based on imidazo[1,2-b]pyridazine, which are inhibitors of the protein kinase HASPIN.

Industrial partners are being sought to collaborate through a patent license agreement for the development and exploitation of the technology.

Description

The inventors have found a novel The present invention relates to a group of compounds with a tricyclic core based on imidazo[1,2-b]pyridazine which are inhibitors of HASPIN, whose activity is required for the proliferation of certain tumoral cells, so the compounds of the invention are useful for the prevention and/or treatment of cancer, alone or in combination with chemotherapeutic agents.

Main innovations and advantages

The novel compounds of the invention are not active for PIM1, thus, they are more selective and less toxic than other compounds of the state of art.

The compounds of the invention are useful for the treatment of cancer that depends on HASPIN, for example, Burkitt's lymphoma, chronic lymphocytic leukemias, pancreatic cancer, gallbladder carcinoma, bladder cancer, prostate cancer, melanoma, breast cancer, or ovarian cancer. They can be used alone or in combination with chemotherapeutic agents, presenting synergistic combination effects.

Intellectual property

Patent title :


“Imidazo[1,2-b]pyridazine based tricyclic compounds as inhibitors of HASPIN and therapeutic uses thereof”

Applicant: Spanish National Cancer Research Center (CNIO)

International patent application:

WO2022200433

Patent extended in: Canada, Europe, Japan and USA.



(I)

For more information, please contact:

Technology Transfer and Valorization Office
Centro Nacional de Investigaciones Oncológicas
C/ Melchor Fernández Almagro, 3
28029 Madrid Spain
technologytransfer@cnio.es
www.cnio.es
@CNIO_Cancer